Wednesday, February 10, 2010, 2:06PM AEST - The Australian Stockmarket closes in 1 hour and 59 minutes.
To create a watchlist or portfolio of shares, Register

Abraxis BioScience, Inc. (ABII)

 8:00AM AEST: 35.22 USD  Down 3.18 (8.28%)  
 MORE ON ABII 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Abraxis Bioscience Inc. (NasdaqNM:ABII) Delayed quote dataEdit
Last Trade:35.22 USD
Trade Time: 8:00AM AEST
Change:Down 3.18 (8.28%)
Prev Close:38.40
Open:38.40
Bid:33.57 x 200
Ask:78.00 x 100
1y Target Est:N/A
Day's Range:34.80 - 38.63
52wk Range:24.52 - 73.98
Volume:165,354
Avg Vol (3m):47,263.5
Market Cap:1.41B
P/E (ttm):N/A
EPS (ttm):-6.63
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add ABII to Portfolio   Download Data

 HEADLINES 
•Abraxis Bioscience to Spin Off Abraxis Health in 2010
at Seeking Alpha (Sun, Jan 31)
•Abraxis BioScience downgraded by Merriman
Briefing.com (Fri, Jan 29)
•ABRAXIS BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Fri, Jan 29)
•Abraxis BioScience Confirms Plan to Spin-off Abraxis Health in 2010 and Announces Management Structure
Business Wire (Fri, Jan 29)
•$10,000 Will Be 2010 Consumable Cost For Human Genome Sequencing: Competition Developing Rapidly In This Sector According To First Analysis Equity Valuation Expert
Wall Street Transcript (Thu, Jan 28)
•Abraxis BioScience to Present at 28th Annual J.P. Morgan Healthcare Conference
Business Wire (Sat, Jan 9)
•ABRAXIS BIOSCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Wed, Dec 16)
•[video] Craig Barrett's Healthy Endeavor
at Forbes.com (Thu, Dec 10)
•Abraxis Provides Overview of ABRAXANE® Study Results to Be Presented at the 32nd Annual San Antonio Breast Cancer Symposium
Business Wire (Wed, Dec 9)
•[$$] Small-Cap Weakness Shrinks a Nanotech ETF
at RealMoney by TheStreet.com (Sat, Nov 28)
•Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Sat, Nov 21)
More Headlines for ABII...
 ANALYST 
EPS Est (next year) (Dec-09) :-3.10
EPS Est (in 2 years) (Dec-10) :-2.13
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices